Target intelligence / Profile preview

UL16-binding protein family (ULBP)

Target
ULBP
Molecular classification
MHC class I-related protein, NKG2D ligand, Glycosylphosphatidylinositol-anchored protein, Transmembrane protein, Other
01

Overview

The UL16-binding protein (ULBP) family, also known as the RAET1 family, comprises six human glycoproteins (ULBP1-6) that function as ligands for the NKG2D activating receptor found on natural killer (NK) cells and various T cell subsets [1][2]. These proteins are structurally homologous to MHC class I molecules but do not present peptides or associate with beta-2 microglobulin [3]. Under normal physiological conditions, ULBPs are minimally expressed on healthy tissues; however, they are rapidly upregulated in response to cellular stressors such as DNA damage, viral infection, or oncogenic transformation [4][5]. This "induced-self" expression marks compromised cells for elimination by the immune system, making the ULBP family a high-priority target for cancer immunotherapies, including CAR-T cells and bispecific engagers [6][7]. Clinical candidates like CYAD-01 utilize the NKG2D receptor to target the broad expression of ULBPs across multiple hematological and solid malignancies [8]. A significant challenge in targeting this family is the proteolytic shedding of ULBPs from the cell surface, which creates soluble decoys that can desensitize NKG2D receptors and facilitate tumor immune evasion [9].

Other names
RAET1 proteinsRetinoic acid early transcript 1 familyNKG2D ligandsUL16-binding proteinsULBP1-6
02

Mechanism of action

Activation of the NKG2D receptor on natural killer (NK) cells and cytotoxic T cells to induce targeted lysis of cells expressing ULBP ligands.

03

Biological functions

Immune responseNatural killer cell activationT cell costimulationStress-induced signalingApoptosis induction
04

Disease associations

CancerInfectionAutoimmune disease
05

Safety considerations

On-target off-tumor toxicity due to low-level expression in healthy tissuesImmune evasion via proteolytic shedding of ligands (soluble decoys)Cytokine release syndrome (CRS) associated with CAR-T therapiesTumor resistance through downregulation of ligands
06

Interacting drugs

CYAD-01

4 more in the full profile.

07

Biomarkers

ULBP1 surface expressionULBP2 surface expressionULBP3 surface expressionSoluble ULBP2 (sULBP2) serum levelsNKG2D ligand density

Beyond the preview

Go deeper on UL16-binding protein family (ULBP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on UL16-binding protein family (ULBP).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call